Sleep apnea device maker Resmed's Q1 revenue edges past estimates on higher demand

ResMed

30/10/2025 20:45

Overview

Resmed fiscal Q1 revenue grows 9% to $1.34 bln, narrowly beating analyst expectations

Adjusted EPS for fiscal Q1 beats consensus, reflecting strong operational performance

Company repurchased 523,000 shares for $150 mln, continuing capital management strategy

Outlook

Company did not provide specific guidance for future quarters or full year in its press release

Result Drivers

SLEEP DEVICES DEMAND - Revenue growth driven by increased demand for sleep devices, masks, and accessories

MARGIN IMPROVEMENT - Gross margin increased due to manufacturing and logistics efficiencies and component cost improvements

RESTRUCTURING CHARGES - $16 mln restructuring charges recorded due to workforce planning activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$1.34 bln
$1.33 bln (16 Analysts)
Q1 Adjusted EPS
Beat
$2.55
$2.49 (13 Analysts)
Q1 EPS
$2.37
Q1 Adjusted Gross Margin
62%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Resmed Inc is $300.00, about 15.5% above its October 29 closing price of $253.62

Press Release: ID:nGNX3BLX2Q

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)